Market Closed -
Xetra
11:36:06 2024-05-09 am EDT
|
5-day change
|
1st Jan Change
|
1.64
EUR
|
0.00%
|
|
+3.80%
|
-13.23%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
59.42
|
20.03
|
7.841
|
6.958
|
1.613
|
1.443
|
-
|
Enterprise Value (EV)
1 |
48.38
|
16.19
|
-15.21
|
-3.168
|
1.613
|
-1.033
|
0.0572
|
P/E ratio
|
-2.97
x
|
-1.68
x
|
-2.91
x
|
-0.57
x
|
-
|
-1.84
x
|
-2.87
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
52.8
x
|
23.8
x
|
1.26
x
|
14.3
x
|
4.75
x
|
-
|
-
|
EV / Revenue
|
43
x
|
19.3
x
|
-2.45
x
|
-6.53
x
|
4.75
x
|
-
|
-
|
EV / EBITDA
|
-3.42
x
|
-1.46
x
|
7.86
x
|
0.28
x
|
-0.3
x
|
1.41
x
|
-0.13
x
|
EV / FCF
|
-3,562,351
x
|
-1,689,401
x
|
3,632,218
x
|
246,152
x
|
-
|
-
|
-
|
FCF Yield
|
-0%
|
-0%
|
0%
|
0%
|
-
|
-
|
-
|
Price to Book
|
5.28
x
|
5.18
x
|
0.45
x
|
0.68
x
|
-
|
-0.71
x
|
-0.46
x
|
Nbr of stocks (in thousands)
|
272
|
295
|
612
|
819
|
853
|
880
|
-
|
Reference price
2 |
218.4
|
68.00
|
12.82
|
8.500
|
1.890
|
1.640
|
1.640
|
Announcement Date
|
4/29/20
|
3/25/21
|
3/24/22
|
4/28/23
|
3/15/24
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
1.125
|
0.84
|
6.203
|
0.485
|
0.3392
|
-
|
-
|
EBITDA
1 |
-14.16
|
-11.09
|
-1.935
|
-11.3
|
-5.298
|
-0.73
|
-0.445
|
EBIT
1 |
-14.67
|
-11.63
|
-2.354
|
-12.05
|
-6.095
|
-0.78
|
-0.5
|
Operating Margin
|
-1,304.27%
|
-1,384.17%
|
-37.95%
|
-2,484.54%
|
-1,796.7%
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-14.57
|
-11.66
|
-2.41
|
-12.1
|
-4.464
|
-0.78
|
-0.5
|
Net income
1 |
-17.02
|
-11.7
|
-2.428
|
-12.02
|
-4.464
|
-0.78
|
-0.5
|
Net margin
|
-1,512.89%
|
-1,392.86%
|
-39.14%
|
-2,479.18%
|
-1,315.78%
|
-
|
-
|
EPS
2 |
-73.60
|
-40.40
|
-4.400
|
-14.80
|
-
|
-0.8918
|
-0.5717
|
Free Cash Flow
|
-13.58
|
-9.581
|
-4.187
|
-12.87
|
-
|
-
|
-
|
FCF margin
|
-1,207.2%
|
-1,140.6%
|
-67.5%
|
-2,653.81%
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/29/20
|
3/25/21
|
3/24/22
|
4/28/23
|
3/15/24
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
11
|
3.84
|
23
|
10.1
|
-
|
2.48
|
1.39
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-13.6
|
-9.58
|
-4.19
|
-12.9
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-121%
|
-173%
|
-18.7%
|
-74.5%
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
41.30
|
13.10
|
28.50
|
12.40
|
-
|
-2.310
|
-3.560
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
0.08
|
0.01
|
0.04
|
0.85
|
-
|
-
|
-
|
Capex / Sales
|
6.67%
|
1.19%
|
0.56%
|
174.64%
|
-
|
-
|
-
|
Announcement Date
|
4/29/20
|
3/25/21
|
3/24/22
|
4/28/23
|
3/15/24
|
-
|
-
|
Last Close Price
1.64
EUR Average target price
15.8
EUR Spread / Average Target +863.41% Consensus |
1st Jan change
|
Capi.
|
---|
| -13.23% | 1.55M | | -26.80% | 10.94B | | +65.44% | 3.75B | | -28.13% | 2.27B | | -10.06% | 2.25B | | -25.01% | 1.54B | | +50.53% | 1.18B | | -2.84% | 754M | | -7.83% | 529M | | -27.35% | 469M |
Bio Diagnostics & Testing
|